Your FTO & MC4R genes might be behind that candy bar obsession.

Get tested now and start getting practical lifestyle advice based on your genetics: thednacompany.com/products/genetic-collect...

#CravingsDecoded #GeneticAppetite #FTOgene #MC4R #Nutrigenomics

Congruence Therapeutics Presents Groundbreaking Treatment for Early-Onset Obesity at Boston Summit Congruence Therapeutics recently showcased its novel MC4R corrector CGX-926 for treating early-onset obesity at a significant summit in Boston.

Congruence Therapeutics Presents Groundbreaking Treatment for Early-Onset Obesity at Boston Summit #USA #Boston #Congruence_Therapeutics #MC4R #CGX-926

Study shows brain estrogen directly regulates appetite in mice Researchers in Japan found that estrogen produced within the brain, called neuroestrogen, suppresses appetite and reduces body weight in mice by enhancing MC4R expression. The study also showed that n...

Study shows brain estrogen directly regulates appetite in mice 🧠🍽️🧬 www.news-medical.net/news/2025050... #appetite #brain #estrogen #neuroestrogen #obesity #weightloss #leptin #neuroscience #metabolism #MC4R

#MC4R certainly shows potential. Will have to see detailed data. For a real medicine though, less frequent, possibly more specificity needed. Or could #RNAediting by mimicking GWAS variants be more potent+safe?

Do you mean #MC4R stands out as top target...?

Palatin Announces MC4R Agonist Bremelanotide Co-Administered with GLP-1/GIP Tirzepatide Meets Primary Endpoint in Phase 2 Obesity Study Palatin Technologies, Inc. (NYSE American: PTN), a biopharmaceutical company developing first-in-class medicines based on molecules that modulate the activity of the melanocortin receptor system, toda...

And today we get proof-of-concept #MC4R receptor agonist #obesity data from #PalatinTechnologies in a 8-week study showing enhanced weight loss when given on top of #tirzepatide:

#$PTN sees opportunity in hypothalamic obesity.

finance.yahoo.com/news/palatin...

As if on cue, #MC4R drops out as top target in #obesity-GWAS meta-analysis. Big effect sizes.

www.nature.com/articles/s41....

Congruence Therapeutics to Showcase Innovations at 24th Annual Needham Virtual Healthcare Conference Congruence Therapeutics will participate in the 24th Annual Needham Virtual Healthcare Conference, presenting its innovative solutions for protein misfolding.

Congruence Therapeutics to Showcase Innovations at 24th Annual Needham Virtual Healthcare Conference #Canada #Montreal #Parkinson's_Disease #Congruence_Therapeutics #MC4R

This research shows the value of dogs as a model for #geneticdiscovery & the power of collaboration between veterinary & human medicine 💡. Huge thanks to our funders: BBSRC, @wellcometrust.bsky.social, @dogstrust.bsky.social & @morrisanimal.bsky.social! #DENND1B #MC4R #science #obesity

un mecanisme a través del qual el receptor no-visual #MC4R (#receptormelanocortina4) de la OPN3 modula la gana de menjar.

La OPN3 i aquest receptor emergeixen així com un mecanisme crític per a la regulació del balanç energètic i el comportament en relació al menjar.

Hypothalamic opsin 3 suppresses MC4R signaling and potentiates Kir7.1 to promote food consumption | PNAS Mammalian opsin 3 (OPN3) is a member of the opsin family of G-protein-coupled receptors with ambiguous light sensitivity. OPN3 was first identified...

Very excited to share my PhD work now out @pnas.org! We discovered the cellular mechanism and function of Opsin 3, a light sensing GPCR, in the hypothalamus.

www.pnas.org/doi/10.1073/...

#GPCR #Opsin #MC4R #Kir7.1 #hypothalamus #feeding